1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.02. | Theseus Pharmaceuticals, Inc. - 15-12G, Securities registration termination | 2 | SEC Filings | ||
| 14.02. | Theseus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.02. | NSE - Theseus Pharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 3 | SEC Filings | ||
| 30.01. | Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals | 233 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--As previously announced on December 22, 2023, Concentra Biosciences, LLC ("Parent") and its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Purchaser"), entered... ► Artikel lesen | |
| 22.12.23 | Small-Cap Cancer Focused Theseus Pharmaceuticals Goes Private For Over $3.90/Share In Cash | 2 | Benzinga.com | ||
| 22.12.23 | Theseus Pharma To Acquire Concentra Biosciences For $4.05/Shr In Cash | 2 | RTTNews | ||
| 22.12.23 | Theseus Pharma rises as Concentra Biosciences agrees to take it private | 2 | Reuters | ||
| 22.12.23 | Theseus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.12.23 | Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right | 171 | PR Newswire | CAMBRIDGE, Mass., Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives... ► Artikel lesen | |
| 04.12.23 | Theseus Pharma terminates CEO and medical chief | 2 | Seeking Alpha | ||
| 04.12.23 | Theseus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.11.23 | US STOCKS Theseus Pharma, Shopify, Mondelez International | 4 | Reuters | ||
| 27.11.23 | Theseus Pharmaceuticals (THRX) Up 57% in a Month on Strategic Restructuring Plan | 1 | Zacks | ||
| 27.11.23 | Theseus Pharma To Evaluate Expression Of Interest From Foresite, OrbiM And Proposal From Concentra | 1 | RTTNews | ||
| 27.11.23 | Theseus Pharmaceuticals discloses buyout interest | 1 | Seeking Alpha | ||
| 27.11.23 | Theseus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.11.23 | Theseus Pharma rises on buyout offer from Concentra | 4 | Reuters | ||
| 20.11.23 | Theseus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary | 1 | Reuters | ||
| 17.11.23 | Theseus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.11.23 | Theseus Pharmaceuticals, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,045 | +4,50 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,946 | +9,75 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 23,130 | +1,80 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,090 | +1,87 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ARCA BIOPHARMA | 3,000 | 0,00 % | ARCA biopharma, Inc.: ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update | ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:... ► Artikel lesen | |
| ASSERTIO | 1,025 | +1,49 % | Assertio Holdings Q1 2024 Earnings Preview | ||
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| PIERIS PHARMACEUTICALS | 11,000 | -2,14 % | PIERIS PHARMACEUTICALS, INC. - 10-K/A, Annual Report | ||
| SIGA TECHNOLOGIES | 10,150 | +7,52 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | -0,20 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,390 | +13,18 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,410 | +4,23 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,750 | +3,07 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen |
THESEUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,060 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
